TXN and cancer: While dual targeting of the TRX and GSH synthesis pathway has previously been identified as a synergistic killing strategy against several cancer entities, so far, reasons as to what the nature of the synergy may be and patient groups which may actually benefit from this regime in clinical trials have not been identified.